ALK and non-small cell lung carcinoma: ALK rearrangements in NSCLC were associated with prolonged progression-free survival (PFS) of patients who received pemetrexed-based chemotherapy before the discovery of crizotinib, a targeted ALK tyrosine kinase inhibitor [7, 8].